APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PET Radiopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PET Radiopharmaceuticals Market Outlook and Growth Opportunities 2026

Report ID 174024330419 December 2025190 pages

Choose your research edition.

Industry ResearchPET Radiopharmaceuticals Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal PET Radiopharmaceuticals Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PET Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PET Radiopharmaceuticals Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal PET Radiopharmaceuticals Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global PET Radiopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PET Radiopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PET Radiopharmaceuticals market include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PET Radiopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PET Radiopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PET Radiopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PET Radiopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.

PET Radiopharmaceuticals Segment by Company

Cardinal Health Inc. (U.S.)

Bayer AG (Germany)

Nordion, Inc. (Canada)

Mallinckrodt plc (Ireland)

Lantheus Medical Imaging, Inc. (U.S.)

IBA Molecular Imaging (Belgium)

GE Healthcare (U.K.)

Eczacibasi-Monrol Nuclear Products (Turkey)

Bracco Imaging S.p.A (Italy)

Advanced Accelerator Applications S.A. (France)

PET Radiopharmaceuticals Segment by Type

F-18

Ru-82

Others

PET Radiopharmaceuticals Segment by Application

Neurology

Cardiology

Oncology

Others

PET Radiopharmaceuticals Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global PET Radiopharmaceuticals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PET Radiopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PET Radiopharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze PET Radiopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PET Radiopharmaceuticals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PET Radiopharmaceuticals industry.

Chapter 3: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PET Radiopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PET Radiopharmaceuticals Industry Trends Table 2. PET Radiopharmaceuticals Industry Drivers Table 3. PET Radiopharmaceuticals Industry Opportunities and Challenges Table 4. PET Radiopharmaceuticals Industry Restraints Table 5. Global PET Radiopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PET Radiopharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global PET Radiopharmaceuticals Sales Volume by Company (K Units) & (2021-2026) Table 8. Global PET Radiopharmaceuticals Sales Volume Share by Company (2021-2026) Table 9. Global PET Radiopharmaceuticals Average Price (US$/Unit) of Company (2021-2026) Table 10. Global PET Radiopharmaceuticals Company Ranking, (2024-2026) & (USD Million) Table 11. Global PET Radiopharmaceuticals Key Company Manufacturing Base & Headquarters Table 12. Global PET Radiopharmaceuticals Company, Product Type & Application Table 13. Global PET Radiopharmaceuticals Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PET Radiopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of F-18 Table 18. Significant Companies of Ru-82 Table 19. Significant Companies of Others Table 20. Global PET Radiopharmaceuticals Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global PET Radiopharmaceuticals Sales Volume by Type (2021-2026) & (K Units) Table 22. Global PET Radiopharmaceuticals Sales Volume by Type (2027-2032) & (K Units) Table 23. Global PET Radiopharmaceuticals Sales Volume Share by Type (2021-2026) Table 24. Global PET Radiopharmaceuticals Sales Volume Share by Type (2027-2032) Table 25. Global PET Radiopharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global PET Radiopharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global PET Radiopharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global PET Radiopharmaceuticals Sales Value Share by Type (2021-2026) Table 29. Global PET Radiopharmaceuticals Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Neurology Table 31. Significant Companies of Cardiology Table 32. Significant Companies of Oncology Table 33. Significant Companies of Others Table 34. Global PET Radiopharmaceuticals Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global PET Radiopharmaceuticals Sales Volume by Application (2021-2026) & (K Units) Table 36. Global PET Radiopharmaceuticals Sales Volume by Application (2027-2032) & (K Units) Table 37. Global PET Radiopharmaceuticals Sales Volume Share by Application (2021-2026) Table 38. Global PET Radiopharmaceuticals Sales Volume Share by Application (2027-2032) Table 39. Global PET Radiopharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global PET Radiopharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global PET Radiopharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global PET Radiopharmaceuticals Sales Value Share by Application (2021-2026) Table 43. Global PET Radiopharmaceuticals Sales Value Share by Application (2027-2032) Table 44. Global PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global PET Radiopharmaceuticals Sales by Region (2021-2026) & (K Units) Table 46. Global PET Radiopharmaceuticals Sales Market Share by Region (2021-2026) Table 47. Global PET Radiopharmaceuticals Sales by Region (2027-2032) & (K Units) Table 48. Global PET Radiopharmaceuticals Sales Market Share by Region (2027-2032) Table 49. Global PET Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global PET Radiopharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global PET Radiopharmaceuticals Sales Value Share by Region (2021-2026) Table 52. Global PET Radiopharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global PET Radiopharmaceuticals Sales Value Share by Region (2027-2032) Table 54. Global PET Radiopharmaceuticals Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global PET Radiopharmaceuticals Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global PET Radiopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global PET Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global PET Radiopharmaceuticals Sales by Country (2021-2026) & (K Units) Table 59. Global PET Radiopharmaceuticals Sales Market Share by Country (2021-2026) Table 60. Global PET Radiopharmaceuticals Sales by Country (2027-2032) & (K Units) Table 61. Global PET Radiopharmaceuticals Sales Market Share by Country (2027-2032) Table 62. Global PET Radiopharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global PET Radiopharmaceuticals Sales Value Market Share by Country (2021-2026) Table 64. Global PET Radiopharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global PET Radiopharmaceuticals Sales Value Market Share by Country (2027-2032) Table 66. Cardinal Health Inc. (U.S.) Company Information Table 67. Cardinal Health Inc. (U.S.) Business Overview Table 68. Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio Table 70. Cardinal Health Inc. (U.S.) Recent Development Table 71. Bayer AG (Germany) Company Information Table 72. Bayer AG (Germany) Business Overview Table 73. Bayer AG (Germany) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio Table 75. Bayer AG (Germany) Recent Development Table 76. Nordion, Inc. (Canada) Company Information Table 77. Nordion, Inc. (Canada) Business Overview Table 78. Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio Table 80. Nordion, Inc. (Canada) Recent Development Table 81. Mallinckrodt plc (Ireland) Company Information Table 82. Mallinckrodt plc (Ireland) Business Overview Table 83. Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio Table 85. Mallinckrodt plc (Ireland) Recent Development Table 86. Lantheus Medical Imaging, Inc. (U.S.) Company Information Table 87. Lantheus Medical Imaging, Inc. (U.S.) Business Overview Table 88. Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio Table 90. Lantheus Medical Imaging, Inc. (U.S.) Recent Development Table 91. IBA Molecular Imaging (Belgium) Company Information Table 92. IBA Molecular Imaging (Belgium) Business Overview Table 93. IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio Table 95. IBA Molecular Imaging (Belgium) Recent Development Table 96. GE Healthcare (U.K.) Company Information Table 97. GE Healthcare (U.K.) Business Overview Table 98. GE Healthcare (U.K.) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio Table 100. GE Healthcare (U.K.) Recent Development Table 101. Eczacibasi-Monrol Nuclear Products (Turkey) Company Information Table 102. Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview Table 103. Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio Table 105. Eczacibasi-Monrol Nuclear Products (Turkey) Recent Development Table 106. Bracco Imaging S.p.A (Italy) Company Information Table 107. Bracco Imaging S.p.A (Italy) Business Overview Table 108. Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio Table 110. Bracco Imaging S.p.A (Italy) Recent Development Table 111. Advanced Accelerator Applications S.A. (France) Company Information Table 112. Advanced Accelerator Applications S.A. (France) Business Overview Table 113. Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio Table 115. Advanced Accelerator Applications S.A. (France) Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. PET Radiopharmaceuticals Distributors List Table 119. PET Radiopharmaceuticals Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. PET Radiopharmaceuticals Product Image Figure 2. Global PET Radiopharmaceuticals Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 4. Global PET Radiopharmaceuticals Sales (2021-2032) & (K Units) Figure 5. Global PET Radiopharmaceuticals Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global PET Radiopharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. F-18 Image Figure 10. Ru-82 Image Figure 11. Others Image Figure 12. Global PET Radiopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global PET Radiopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global PET Radiopharmaceuticals Sales Volume Share by Type (2021-2032) Figure 15. Global PET Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global PET Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global PET Radiopharmaceuticals Sales Value Share by Type (2021-2032) Figure 18. Neurology Image Figure 19. Cardiology Image Figure 20. Oncology Image Figure 21. Others Image Figure 22. Global PET Radiopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global PET Radiopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global PET Radiopharmaceuticals Sales Volume Share by Application (2021-2032) Figure 25. Global PET Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global PET Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global PET Radiopharmaceuticals Sales Value Share by Application (2021-2032) Figure 28. Global PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global PET Radiopharmaceuticals Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global PET Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global PET Radiopharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 33. North America PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 35. Europe PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 39. South America PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. PET Radiopharmaceuticals Value Chain Figure 127. Manufacturing Cost Structure Figure 128. PET Radiopharmaceuticals Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • F-18
  • Ru-82
  • Others
Applications
  • Neurology
  • Cardiology
  • Oncology
  • Others
Companies covered
  • Cardinal Health Inc. (U.S.)
  • Bayer AG (Germany)
  • Nordion, Inc. (Canada)
  • Mallinckrodt plc (Ireland)
  • Lantheus Medical Imaging, Inc. (U.S.)
  • IBA Molecular Imaging (Belgium)
  • GE Healthcare (U.K.)
  • Eczacibasi-Monrol Nuclear Products (Turkey)
  • Bracco Imaging S.p.A (Italy)
  • Advanced Accelerator Applications S.A. (France)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PET Radiopharmaceuticals Sales Value (2021-2032)
  4. 1.2.2 Global PET Radiopharmaceuticals Sales Volume (2021-2032)
  5. 1.2.3 Global PET Radiopharmaceuticals Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PET Radiopharmaceuticals Market Dynamics
  1. 2.1 PET Radiopharmaceuticals Industry Trends
  2. 2.2 PET Radiopharmaceuticals Industry Drivers
  3. 2.3 PET Radiopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 PET Radiopharmaceuticals Industry Restraints
3 PET Radiopharmaceuticals Market by Company
  1. 3.1 Global PET Radiopharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global PET Radiopharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global PET Radiopharmaceuticals Sales Volume by Company (2021-2026)
  4. 3.4 Global PET Radiopharmaceuticals Average Price by Company (2021-2026)
  5. 3.5 Global PET Radiopharmaceuticals Company Ranking (2024-2026)
  6. 3.6 Global PET Radiopharmaceuticals Company Manufacturing Base and Headquarters
  7. 3.7 Global PET Radiopharmaceuticals Company Product Type and Application
  8. 3.8 Global PET Radiopharmaceuticals Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PET Radiopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PET Radiopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PET Radiopharmaceuticals Market by Type
  1. 4.1 PET Radiopharmaceuticals Type Introduction
  2. 4.1.1 F-18
  3. 4.1.2 Ru-82
  4. 4.1.3 Others
  5. 4.2 Global PET Radiopharmaceuticals Sales Volume by Type
  6. 4.2.1 Global PET Radiopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PET Radiopharmaceuticals Sales Volume by Type (2021-2032)
  8. 4.2.3 Global PET Radiopharmaceuticals Sales Volume Share by Type (2021-2032)
  9. 4.3 Global PET Radiopharmaceuticals Sales Value by Type
  10. 4.3.1 Global PET Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global PET Radiopharmaceuticals Sales Value by Type (2021-2032)
  12. 4.3.3 Global PET Radiopharmaceuticals Sales Value Share by Type (2021-2032)
5 PET Radiopharmaceuticals Market by Application
  1. 5.1 PET Radiopharmaceuticals Application Introduction
  2. 5.1.1 Neurology
  3. 5.1.2 Cardiology
  4. 5.1.3 Oncology
  5. 5.1.4 Others
  6. 5.2 Global PET Radiopharmaceuticals Sales Volume by Application
  7. 5.2.1 Global PET Radiopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global PET Radiopharmaceuticals Sales Volume by Application (2021-2032)
  9. 5.2.3 Global PET Radiopharmaceuticals Sales Volume Share by Application (2021-2032)
  10. 5.3 Global PET Radiopharmaceuticals Sales Value by Application
  11. 5.3.1 Global PET Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global PET Radiopharmaceuticals Sales Value by Application (2021-2032)
  13. 5.3.3 Global PET Radiopharmaceuticals Sales Value Share by Application (2021-2032)
6 PET Radiopharmaceuticals Regional Sales and Value Analysis
  1. 6.1 Global PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PET Radiopharmaceuticals Sales by Region (2021-2032)
  3. 6.2.1 Global PET Radiopharmaceuticals Sales by Region: 2021-2026
  4. 6.2.2 Global PET Radiopharmaceuticals Sales by Region (2027-2032)
  5. 6.3 Global PET Radiopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PET Radiopharmaceuticals Sales Value by Region (2021-2032)
  7. 6.4.1 Global PET Radiopharmaceuticals Sales Value by Region: 2021-2026
  8. 6.4.2 Global PET Radiopharmaceuticals Sales Value by Region (2027-2032)
  9. 6.5 Global PET Radiopharmaceuticals Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PET Radiopharmaceuticals Sales Value (2021-2032)
  12. 6.6.2 North America PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PET Radiopharmaceuticals Sales Value (2021-2032)
  15. 6.7.2 Europe PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PET Radiopharmaceuticals Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PET Radiopharmaceuticals Sales Value (2021-2032)
  21. 6.9.2 South America PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PET Radiopharmaceuticals Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 PET Radiopharmaceuticals Country-level Sales and Value Analysis
  1. 7.1 Global PET Radiopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PET Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PET Radiopharmaceuticals Sales by Country (2021-2032)
  4. 7.3.1 Global PET Radiopharmaceuticals Sales by Country (2021-2026)
  5. 7.3.2 Global PET Radiopharmaceuticals Sales by Country (2027-2032)
  6. 7.4 Global PET Radiopharmaceuticals Sales Value by Country (2021-2032)
  7. 7.4.1 Global PET Radiopharmaceuticals Sales Value by Country (2021-2026)
  8. 7.4.2 Global PET Radiopharmaceuticals Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cardinal Health Inc. (U.S.)
  2. 8.1.1 Cardinal Health Inc. (U.S.) Company Information
  3. 8.1.2 Cardinal Health Inc. (U.S.) Business Overview
  4. 8.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
  6. 8.1.5 Cardinal Health Inc. (U.S.) Recent Developments
  7. 8.2 Bayer AG (Germany)
  8. 8.2.1 Bayer AG (Germany) Company Information
  9. 8.2.2 Bayer AG (Germany) Business Overview
  10. 8.2.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
  12. 8.2.5 Bayer AG (Germany) Recent Developments
  13. 8.3 Nordion, Inc. (Canada)
  14. 8.3.1 Nordion, Inc. (Canada) Company Information
  15. 8.3.2 Nordion, Inc. (Canada) Business Overview
  16. 8.3.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
  18. 8.3.5 Nordion, Inc. (Canada) Recent Developments
  19. 8.4 Mallinckrodt plc (Ireland)
  20. 8.4.1 Mallinckrodt plc (Ireland) Company Information
  21. 8.4.2 Mallinckrodt plc (Ireland) Business Overview
  22. 8.4.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
  24. 8.4.5 Mallinckrodt plc (Ireland) Recent Developments
  25. 8.5 Lantheus Medical Imaging, Inc. (U.S.)
  26. 8.5.1 Lantheus Medical Imaging, Inc. (U.S.) Company Information
  27. 8.5.2 Lantheus Medical Imaging, Inc. (U.S.) Business Overview
  28. 8.5.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
  30. 8.5.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments
  31. 8.6 IBA Molecular Imaging (Belgium)
  32. 8.6.1 IBA Molecular Imaging (Belgium) Company Information
  33. 8.6.2 IBA Molecular Imaging (Belgium) Business Overview
  34. 8.6.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
  36. 8.6.5 IBA Molecular Imaging (Belgium) Recent Developments
  37. 8.7 GE Healthcare (U.K.)
  38. 8.7.1 GE Healthcare (U.K.) Company Information
  39. 8.7.2 GE Healthcare (U.K.) Business Overview
  40. 8.7.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
  42. 8.7.5 GE Healthcare (U.K.) Recent Developments
  43. 8.8 Eczacibasi-Monrol Nuclear Products (Turkey)
  44. 8.8.1 Eczacibasi-Monrol Nuclear Products (Turkey) Company Information
  45. 8.8.2 Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview
  46. 8.8.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
  48. 8.8.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments
  49. 8.9 Bracco Imaging S.p.A (Italy)
  50. 8.9.1 Bracco Imaging S.p.A (Italy) Company Information
  51. 8.9.2 Bracco Imaging S.p.A (Italy) Business Overview
  52. 8.9.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
  54. 8.9.5 Bracco Imaging S.p.A (Italy) Recent Developments
  55. 8.10 Advanced Accelerator Applications S.A. (France)
  56. 8.10.1 Advanced Accelerator Applications S.A. (France) Company Information
  57. 8.10.2 Advanced Accelerator Applications S.A. (France) Business Overview
  58. 8.10.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
  60. 8.10.5 Advanced Accelerator Applications S.A. (France) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PET Radiopharmaceuticals Value Chain Analysis
  2. 9.1.1 PET Radiopharmaceuticals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PET Radiopharmaceuticals Sales Mode & Process
  6. 9.2 PET Radiopharmaceuticals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PET Radiopharmaceuticals Distributors
  9. 9.2.3 PET Radiopharmaceuticals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst